On January 30, 2018, the Government of Canada posted the Comprehensive and Progressive Partnership for Trans-Pacific Partnership (CPTPP) - Backgrounder. According to the Backgrounder, Canada and other signatories agreed to suspend certain obligations under the Trans-Pacific Partnership (TPP) with respect to intellectual property, patents and pharmaceuticals, including on patent term adjustments to compensate for unreasonable patent office delays and marketing authorization delays. Canada already provides for patent term extension for marketing authorization delays under the Patent Act and Certificate of Supplementary Protection Regulations which came into force September 21, 2017 (as previously reported). On February 20, 2018, Global Affairs Canada subsequently issued a news release announcing the release of the full text of the CPTPP and projected economic impacts of the CPTPP on Canada.
Related Publications & Articles
-
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More